Fibromyalgia & Widespread Pain Treatment in Birmingham & Bessemer, AL

Fibromyalgia Treatment at Alabama Pain Physicians

Fibromyalgia is real, it's common, and it responds to treatment when approached correctly. Our physicians understand that fibromyalgia involves the entire nervous system — not just sore muscles — and we treat it comprehensively.

Your treatment plan may include:

• Medical management — FDA-approved medications for fibromyalgia including duloxetine, milnacipran, and pregabalin, plus careful medication optimization
• Trigger point injections — targeted relief for specific painful muscle areas
• Sleep optimization — addressing the sleep dysfunction that drives fibromyalgia symptoms
• Low-dose naltrexone (LDN) — emerging evidence-based treatment for central sensitization
• Medical marijuana certification — many fibromyalgia patients qualify and report significant improvement in sleep and pain
• Medication review and tapering — optimizing or reducing medications that may be making symptoms worse

If you've been told "there's nothing we can do" for your fibromyalgia, we disagree. There are real, evidence-based treatments that help — and we'll work with you to find the right combination.

Understanding Fibromyalgia: A Multi-System Perspective

The following publication by Ty Thomas, MD explores the deeper biological mechanisms behind why fibromyalgia develops and persists. This research informs how we approach complex and treatment-resistant cases at Alabama Pain Physicians.

Author’s Statement

I am a board-certified Physical Medicine and Rehabilitation physician with additional certification in Venous and Lymphatic Medicine. For over fifteen years at Alabama Pain Physicians, I have managed thousands of patients with chronic pain conditions including fibromyalgia, chronic widespread pain, and central sensitization syndromes. The consistent observation that drives this publication series is the limited, partial treatment response that characterizes chronic pain management across conventional modalities. FDA-approved medications for fibromyalgia help approximately 1 in 10 patients achieve substantial pain relief beyond placebo. The response is bimodal — patients either respond well or not at all. Pain benefits do not consistently translate to improvements in fatigue, sleep, or cognition. These partial responses are not clinical failures in the traditional sense — each intervention does what it is designed to do. They are evidence that the interventions are addressing only one component of a multi-component problem.

This observation led me to cellular systems biology and theory as a framework for understanding the clinical entities I encounter daily. The concept that fibromyalgia and widespread pain emerge from dynamic interactions across metabolic, inflammatory, hormonal, microbiome, mitochondrial, vascular, and structural domains — rather than from a single central sensitization mechanism — makes clinical sense and has improved outcomes in my practice. I have spent years developing assessment protocols, building laboratory infrastructure through CLIA-certified laboratories, and studying the biological pathways that connect these domains. I own clinics, laboratories, and value-based care companies with the goal of providing patients better outcomes. Better outcomes require questioning our current understanding and applying different conceptual frameworks to better explain pathology and wellness. I believe the cellular systems approach provides a more complete lens for understanding fibromyalgia.

These publications are my attempt to provide information about this understanding — how common clinical manifestations of pain can be explained, diagnosed, and treated through cellular systems analysis. They are not a claim to have found a root cause. They are a framework for asking better questions.

Abstract

Background: Fibromyalgia affects 2–8% of the global population and is characterized by widespread pain, fatigue, cognitive dysfunction, and sleep disturbance (Häuser et al., Nature Reviews Disease Primers, 2015; Soroosh et al., International Journal of Rheumatic Diseases, 2024). Current pharmacological treatments — duloxetine, pregabalin, and milnacipran — produce substantial pain relief (≥50% reduction) in approximately 1 in 10 patients with moderate or severe pain, with no evidence of efficacy beyond six months (Rheumatology/Oxford Cochrane overview, 2025). The bimodal response pattern, limited cross-symptom efficacy, and modest treatment effect sizes suggest that single-pathway interventions are insufficient for a condition involving multiple biological systems.

Methods: We conducted a narrative review of PubMed-indexed literature examining fibromyalgia through the lens of cellular systems theory, which proposes that fibromyalgia emerges from dynamic interactions across multiple biological domains rather than dysfunction in any single pathway. We reviewed evidence for metabolic, mitochondrial, inflammatory, neuroendocrine, microbiome, vascular, and structural domain involvement, analyzed treatment response data for FDA-approved medications, and constructed composite clinical scenarios illustrating individualized multi-domain assessment and intervention.

Results: Published evidence demonstrates measurable dysfunction across multiple biological domains in fibromyalgia: insulin resistance markers in 100% of a tested cohort (Pappolla et al., Pain Physician, 2021), NLRP3 inflammasome activation with coenzyme Q10 deficiency (Cordero et al., Journal of Clinical Medicine, 2014), altered gut microbiome composition correlating with symptom severity (Minerbi et al., Pain, 2019), small fiber neuropathy on skin biopsy (Uceyler et al., Brain, 2013), combined systemic and neuroinflammation (Bäckryd et al., Journal of Pain Research, 2017), HPA axis dysregulation (Riva et al., International Journal of Behavioral Medicine, 2010), and peripheral microvascular pathology (Albrecht et al., Pain Medicine, 2013). Current FDA-approved treatments each target a single neurotransmitter pathway: pregabalin modulates calcium channel α2-δ subunits (NNT 9.7 for ≥50% pain relief at optimal dose; Derry et al., Cochrane, 2016), duloxetine inhibits serotonin-norepinephrine reuptake (NNT 8; Lunn et al., Cochrane, 2014), and milnacipran inhibits the same pathway with an NNT of 19 for 30% pain reduction (Häuser et al., pooled analysis). Side effects of these single-pathway agents, including weight gain and metabolic disruption, may worsen the domains they do not treat.

Conclusions: The pattern of multi-domain biological dysfunction combined with limited, partial, bimodal response to single-pathway pharmacotherapy supports the hypothesis that fibromyalgia represents a multi-system cellular disorder requiring individualized, domain-specific intervention protocols. Cellular systems theory provides a framework for identifying which domains are dysfunctional in each patient, directing intervention toward those domains, and measuring biological change through serial laboratory reassessment. Emerging peptide therapeutics operating across metabolic, mitochondrial, inflammatory, neuroendocrine, and tissue repair pathways offer potential for domain-targeted intervention, though clinical evidence for their application in fibromyalgia remains largely preclinical.

1. Introduction

Fibromyalgia is a chronic pain disorder characterized by widespread musculoskeletal pain, fatigue, cognitive dysfunction, sleep disturbance, and psychiatric comorbidity including depression and anxiety (Clauw, JAMA, 2014; Häuser et al., Nature Reviews Disease Primers, 2015). The condition affects approximately 2–8% of the global population (Soroosh et al., International Journal of Rheumatic Diseases, 2024), with chronic widespread pain — its cardinal symptom — present in 7.3–12.9% of the general population across countries (Buskila, Current Pain and Headache Reports, 2003). Approximately 84% of fibromyalgia patients carry at least one comorbid disorder, including musculoskeletal conditions (67%), psychological disorders (35%), and gastrointestinal disorders (27%), with an average diagnostic delay of 2.3 years (Soroosh et al., International Journal of Rheumatic Diseases, 2024).

The prevailing model classifies fibromyalgia as a disorder of central pain processing. Central sensitization — a state of neural hyperexcitability in the central nervous system producing pain hypersensitivity, expanded receptive fields, and allodynia — is considered the defining mechanism (Woolf, Pain, 2011; Latremoliere and Woolf, Journal of Pain, 2009). This framework has driven the development and approval of three pharmacological agents: pregabalin (calcium channel α2-δ modulation), duloxetine (serotonin-norepinephrine reuptake inhibition), and milnacipran (serotonin-norepinephrine reuptake inhibition). Each targets a single neurotransmitter pathway hypothesized to be involved in central pain amplification.

However, the clinical performance of these agents challenges the sufficiency of the single-pathway model. A 2025 Cochrane overview analyzing 21 systematic reviews encompassing 87 trials and 17,631 patients found that all three FDA-approved medications produced substantial pain relief (≥50% reduction) in approximately 1 in 10 patients with moderate or severe fibromyalgia pain, with numbers needed to treat ranging from 6.9 to 14 and no evidence of efficacy beyond six months (Rheumatology/Oxford, 2025). Importantly, pain benefits were not consistently associated with improvements in other cardinal symptoms including fatigue, sleep disturbance, and cognitive dysfunction. Responder analysis of pregabalin trials revealed a bimodal distribution: patients generally experienced either substantial pain relief or minimal benefit, with few achieving an intermediate response (Straube et al., BMC Musculoskeletal Disorders, 2010). This bimodal pattern is inconsistent with a normally distributed single-mechanism disorder but consistent with a condition in which multiple distinct biological mechanisms contribute variably across patients.

This review proposes cellular systems theory as an explanatory framework for fibromyalgia. Rather than classifying fibromyalgia as a single-pathway disorder amenable to single-pathway treatment, cellular systems theory proposes that fibromyalgia emerges from dynamic interactions across multiple biological domains — metabolic, mitochondrial, inflammatory, neuroendocrine, microbiome, vascular, and structural — and that the variability in treatment response reflects variability in which domains are dysfunctional in each individual patient. The clinical implication is that treatment must be individualized based on objective domain assessment rather than applied as a standardized protocol.

2. Methods

We conducted a narrative review of PubMed-indexed literature examining biological domain dysfunction in fibromyalgia. Search terms included fibromyalgia combined with insulin resistance, mitochondrial dysfunction, NLRP3 inflammasome, neuroinflammation, cytokines, HPA axis, cortisol, microbiome, intestinal permeability, small fiber neuropathy, microvascular dysfunction, oxidative stress, central sensitization, and treatment response. We included systematic reviews, meta-analyses, randomized controlled trials, and observational studies published in English-language peer-reviewed journals. We analyzed treatment response data from Cochrane systematic reviews of FDA-approved fibromyalgia medications to characterize the efficacy limitations of single-pathway pharmacotherapy. We constructed composite clinical scenarios based on published laboratory patterns and clinical presentations to illustrate the application of cellular systems theory to individualized assessment and treatment.

3. The Limitations of Single-Pathway Pharmacotherapy

The three FDA-approved pharmacological treatments for fibromyalgia each target a single neurotransmitter pathway. Their treatment effect data, drawn from Cochrane systematic reviews and pooled analyses, reveal a consistent pattern of limited, partial, and bimodal efficacy.

3.1 Pregabalin

Pregabalin binds the α2-δ subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release at hyperexcitable synapses. In a Cochrane review of five randomized controlled trials including 3,283 fibromyalgia patients, the number needed to treat (NNT) for at least 50% pain relief at the optimal dose of 450 mg daily was 9.7 (95% CI 7.2–15), meaning approximately 10 patients must be treated for one to achieve substantial pain relief beyond placebo (Derry et al., Cochrane Database of Systematic Reviews, 2016). After 12 weeks at 450 mg, only 21% of patients achieved substantial (≥50%) pain response compared with 14% on placebo — an absolute benefit of approximately 9% (Straube et al., BMC Musculoskeletal Disorders, 2010). The response plateaued at 4–6 weeks; patients not responding by that time were unlikely to respond subsequently. Response was bimodal rather than normally distributed.

Pregabalin’s most clinically significant adverse effect in the context of cellular systems theory is weight gain. In clinical trials, weight gain was dose-dependent and occurred at NNH values as low as 4–5 at higher doses. Weight gain worsens insulin resistance — the metabolic abnormality documented in 100% of a tested fibromyalgia cohort by Pappolla et al. (Pain Physician, 2021). A single-pathway intervention that improves calcium channel function while simultaneously worsening the metabolic domain illustrates the fundamental limitation of domain-unaware treatment: adjusting one pathway without monitoring the others can destabilize the biological system.

3.2 Duloxetine

Duloxetine inhibits reuptake of serotonin and norepinephrine, increasing their availability in descending pain-inhibitory pathways. A Cochrane review found an NNT of 8 (95% CI 4–21) for at least 50% pain relief in fibromyalgia over 12 weeks, with the Cochrane authors noting that an NNT of 8 “is not an indication of substantial efficacy” (Lunn et al., Cochrane Database of Systematic Reviews, 2014). A pooled analysis of six trials found that 41% of patients achieved 50% pain relief with duloxetine compared with 24% on placebo, but the response distribution was bimodal — patients generally experienced either very good or very poor relief, with few having the average response (Sultan et al., BMC Neurology, 2008). Individual patient data analysis confirmed that response was not normally distributed, rendering mean pain score changes a poor descriptor of treatment effect (Moore et al., European Journal of Pain, 2014).

Duloxetine’s effect in fibromyalgia may be achieved more through improvement in mental symptoms than somatic physical pain (Lunn et al., Cochrane, 2014). This observation is consistent with cellular systems theory: duloxetine addresses the neurotransmitter component of the neuroendocrine domain but does not address the metabolic, mitochondrial, inflammatory, or microbiome domains that may be driving the somatic pain component. In a patient whose pain is primarily driven by gut-derived inflammation and insulin resistance, an intervention targeting serotonin-norepinephrine reuptake addresses the wrong domain.

3.3 Milnacipran

Milnacipran, a second serotonin-norepinephrine reuptake inhibitor approved for fibromyalgia, showed the weakest efficacy of the three agents. Häuser et al., in a pooled analysis of 11 randomized controlled trials enrolling 6,388 patients that indirectly compared all three drugs, found NNTs for 30% pain reduction of 7.2 for duloxetine, 8.6 for pregabalin, and 19 for milnacipran. There was no significant difference among the three drugs in achieving a minimum 30% pain reduction. Discontinuation rates due to adverse events were similar across agents.

3.4 Synthesis: The Pattern of Partial Response

Across all three FDA-approved agents, the data converge on a consistent pattern: approximately 1 in 10 patients with moderate or severe fibromyalgia pain achieves substantial pain relief beyond placebo. The response is bimodal. Pain benefits do not consistently translate to improvements in fatigue, sleep, or cognition. There is no evidence of efficacy beyond six months. Each agent targets a single neurotransmitter mechanism.

This pattern is precisely what would be predicted by a multi-domain disorder. If fibromyalgia involves variable dysfunction across metabolic, mitochondrial, inflammatory, neuroendocrine, microbiome, vascular, and structural domains, and each patient’s syndrome reflects a unique combination of domain dysfunction, then a single-pathway agent would be expected to help only the subset of patients in whom that pathway’s domain is the dominant driver. The remaining patients — whose pain is primarily driven by domains the medication does not address — would experience minimal benefit. The bimodal response distribution is the signature of a multi-domain disorder being treated with single-domain interventions.

Furthermore, the side effects of single-pathway agents can actively worsen domains they do not target. Pregabalin-induced weight gain worsens insulin resistance. Duloxetine can disrupt sleep architecture, potentially worsening the neuroendocrine domain. All three agents can produce gastrointestinal side effects that may worsen gut barrier function. In a multi-domain disorder, treating one domain while destabilizing others does not produce net clinical improvement — it shifts the burden from one biological system to another.

4. Evidence for Multi-Domain Dysfunction in Fibromyalgia

4.1 Mitochondrial Function and Metabolic Dysfunction

Cordero et al. demonstrated that coenzyme Q10 — an essential component of the mitochondrial electron transport chain, the molecular machinery that produces cellular energy in the form of ATP — is deficient in fibromyalgia patients, and that the NLRP3 inflammasome (a danger-sensing molecular complex that activates inflammatory cascades when it detects cellular distress signals) is abnormally activated in their blood mononuclear cells. Supplementation with coenzyme Q10 reduced NLRP3 activation and improved clinical symptoms (Cordero et al., Journal of Clinical Medicine, 2014). An earlier study found significantly elevated oxidative stress markers alongside mitochondrial dysfunction (Cordero et al., Neuro Endocrinology Letters, 2010). Meeus et al. proposed that oxidative and nitrosative stress-induced mitochondrial damage plays a central role in fibromyalgia pain and fatigue (Meeus et al., Medical Hypotheses, 2013).

Pappolla et al. found that fibromyalgia patients could be segregated from two control populations by HbA1c levels (P < 0.0001 and P = 0.0002), and that 100% of a subgroup analyzed with insulin resistance indices (QUICKI and HOMA-IR) exhibited laboratory abnormalities consistent with insulin resistance. The investigators hypothesized that insulin resistance causes cerebral microvascular dysfunction leading to focal brain hypoperfusion, a pattern separately documented in fibromyalgia imaging studies (Pappolla et al., Pain Physician, 2021). This is a small observational study (33 patients) requiring replication, but it identifies a measurable, potentially modifiable metabolic abnormality present across the tested cohort.

4.2 Immune Surveillance and Inflammation

Bäckryd et al. demonstrated both systemic and neuroinflammation in fibromyalgia, with cerebrospinal fluid inflammatory markers that were not simply reflections of peripheral inflammation (Bäckryd et al., Journal of Pain Research, 2017). A meta-analysis found significantly altered cytokine profiles including elevated interleukin-6 and interleukin-8 (Uçeyler et al., BMC Musculoskeletal Disorders, 2011). Littlejohn and Guymer described neurogenic inflammation in which peripheral nerve activation releases inflammatory neuropeptides amplifying pain processing (Littlejohn and Guymer, Seminars in Immunopathology, 2018). Theoharides et al. documented mast cell activation with histamine, tryptase, and cytokine release directly activating pain pathways — a mechanism distinct from classical NF-κB-driven inflammation (Theoharides et al., Frontiers in Cellular Neuroscience, 2019). The NLRP3 inflammasome activation documented by Cordero et al. (2014) connects the immune domain to the mitochondrial domain through a self-reinforcing loop: mitochondrial dysfunction produces oxidative stress, which activates the inflammasome, which produces cytokines that further damage mitochondria.

4.3 Neuroendocrine Regulation

HPA axis dysregulation is consistently documented. Riva et al. demonstrated hypocortisolism in fibromyalgia, reflecting HPA axis exhaustion (Riva et al., International Journal of Behavioral Medicine, 2010). Heim et al. described the trajectory from stress-induced cortisol elevation to eventual depletion (Heim et al., Psychoneuroendocrinology, 2000). McBeth et al. found altered HPA function in chronic widespread pain (McBeth et al., Journal of Rheumatology, 2005). Non-restorative sleep independently predicts pain severity and disability, preceding and amplifying pain rather than simply resulting from it (Choy, Nature Reviews Rheumatology, 2015; Finan et al., Journal of Pain, 2013). Central sensitization is maintained by spinal cord microglia and astrocytes releasing proinflammatory cytokines that enhance synaptic pain transmission (Watkins and Maier, Physiological Reviews, 2002; Woolf, Pain, 2011), connecting the immune domain directly to central pain amplification.

4.4 Microbiome and Mucosal Immunity

Minerbi et al. found distinct gut microbiome alterations in fibromyalgia, with specific bacterial taxa correlating with pain severity, fatigue, cognitive symptoms, and sleep disturbance. Machine learning algorithms classified patients with reported accuracy exceeding 87% based on microbiome composition alone (Minerbi et al., Pain, 2019). SIBO is associated with fibromyalgia prevalence (Erdrich et al., Clinical and Experimental Rheumatology, 2020). Gut barrier dysfunction allows bacterial lipopolysaccharide to translocate into systemic circulation, activating NF-κB-mediated inflammatory cascades (Camilleri, Gut, 2019) that may drive the systemic inflammation feeding central sensitization, while simultaneously promoting insulin resistance through cytokine-mediated metabolic disruption.

4.5 Detoxification and Oxidative Stress

Ozgocmen et al. documented elevated lipid peroxidation and altered nitric oxide metabolism with reduced antioxidant capacity in fibromyalgia (Ozgocmen et al., Clinical Rheumatology, 2006). Glutathione depletion from chronic oxidative stress removes both the primary antioxidant defense and the primary Phase II detoxification molecule responsible for clearing inflammatory prostaglandins and leukotrienes. This connects the detoxification domain to both the mitochondrial domain (oxidative stress from electron transport chain dysfunction) and the inflammatory domain (impaired clearance of inflammatory mediators).

4.6 Vascular and Microvascular Dysfunction

Albrecht et al. discovered excessive peptidergic sensory innervation of cutaneous arteriole-venule shunts in fibromyalgia patients, providing a peripheral vascular mechanism for widespread pain and temperature sensitivity (Albrecht et al., Pain Medicine, 2013). This finding demonstrates measurable peripheral vascular pathology in a condition conventionally classified as a central nervous system disorder, supporting the multi-domain model.

4.7 Structural Domain: Small Fiber Neuropathy

Uceyler et al. demonstrated significantly reduced intraepidermal nerve fiber density in fibromyalgia patients on skin biopsy (Uceyler et al., Brain, 2013), providing objective structural evidence of peripheral nerve damage. This connects fibromyalgia to the broader neuropathy literature and identifies a structural domain abnormality that single-pathway neurotransmitter agents do not address.

5. Inter-Domain Cascade Mechanics

Cellular systems theory proposes that the domains described above do not operate independently but interact dynamically, with dysfunction in one domain amplifying dysfunction in others. The following cascades are supported by the evidence reviewed above.

5.1 Metabolic-Inflammatory-Central Sensitization Cascade

Insulin resistance (Pappolla et al., 2021) promotes systemic inflammation through adipose-derived cytokine production and NF-κB activation (Niederberger and Geisslinger, FASEB Journal, 2008). Systemic inflammatory mediators activate spinal cord microglia, amplifying pain signaling and producing central sensitization (Watkins and Maier, 2002; Woolf, 2011). Pain itself worsens insulin resistance through the bidirectional pain-insulin resistance relationship documented in animal models (Zhai et al., Journal of Pain, 2016). Pregabalin-induced weight gain may further worsen insulin resistance, potentially accelerating this cascade in treated patients.

5.2 Gut-Immune-Brain Cascade

Gut microbiome alterations (Minerbi et al., 2019) and intestinal barrier dysfunction (Camilleri, 2019) produce systemic endotoxemia and NF-κB-driven inflammation. The resulting inflammatory tone activates spinal cord glial cells driving central sensitization. Gut dysbiosis alters tryptophan metabolism, reducing serotonin availability and weakening descending pain inhibition. SIBO (Erdrich et al., 2020) amplifies this cascade. Gastrointestinal side effects from duloxetine and milnacipran — reported at NNH values of 6–18 across adverse effect categories (Lunn et al., 2014) — may worsen gut barrier function in patients with active microbiome domain dysfunction.

5.3 Sleep-Hormone-Repair Cascade

Non-restorative sleep (Choy, 2015) reduces deep sleep-dependent growth hormone release, impairing tissue repair and immune regulation. Sleep disruption drives HPA axis dysregulation progressing from cortisol elevation to hypocortisolism (Heim et al., 2000; Riva et al., 2010). Low cortisol removes inflammatory inhibition. Pain and fatigue reduce physical activity, worsening insulin sensitivity, reducing mitochondrial density, and eliminating the anti-inflammatory and neurotrophic benefits of exercise. Pregabalin produces somnolence (NNH 11; Lunn et al., 2014), which may mask sleep architecture disruption rather than restoring restorative sleep.

5.4 Mitochondrial-Oxidative-Inflammasome Cascade

Mitochondrial dysfunction produces excess reactive oxygen species (Cordero et al., 2010). Coenzyme Q10 deficiency impairs electron transport chain efficiency, increasing oxidative stress, which activates the NLRP3 inflammasome (Cordero et al., 2014). The inflammasome produces IL-1β and IL-18, which further damage mitochondria, creating a self-reinforcing loop. ATP depletion from mitochondrial dysfunction contributes directly to fatigue. None of the three FDA-approved agents addresses mitochondrial function, coenzyme Q10 status, or NLRP3 inflammasome activation.

6. Clinical Scenarios: Individualized Domain Assessment

The following composite clinical scenarios illustrate how cellular systems theory guides individualized assessment and intervention. Patient details are constructed from published laboratory patterns and clinical presentations described in the literature reviewed above. All laboratory values represent plausible clinical findings consistent with the domain dysfunction documented in the cited studies.

6.1 Patient A: Metabolic-Mitochondrial Dominant Pattern

Presentation: 48-year-old woman with 6-year history of widespread pain meeting ACR criteria for fibromyalgia, severe fatigue rated 8/10, non-restorative sleep despite adequate sleep duration, cognitive difficulty (“fibro fog”), BMI 34. Previous trials of pregabalin (weight gain of 12 pounds, discontinued) and duloxetine (partial improvement in mood, minimal change in pain or fatigue). Current pain 7/10 on numerical rating scale.

Domain Assessment — Laboratory Findings: Fasting insulin 22 µIU/mL (elevated; reference <10), HbA1c 5.8% (prediabetic range), HOMA-IR 5.1 (elevated; reference <2.0), triglyceride-to-glucose ratio elevated. hs-CRP 4.2 mg/L (elevated systemic inflammation). Diurnal cortisol curve flattened with low morning cortisol (3.8 µg/dL; reference 10–20) and loss of normal diurnal variation. Vitamin D 18 ng/mL (deficient; reference 50–80). Organic acids testing showing elevated succinic acid and suberic acid (markers consistent with mitochondrial dysfunction and impaired fatty acid oxidation). Omega-3 index 3.2% (critically low; reference >8%).

Domain Interpretation: This patient’s laboratory pattern is consistent with the metabolic-inflammatory-central sensitization cascade. Insulin resistance (HOMA-IR 5.1) is present at the level documented by Pappolla et al. (2021) as associated with fibromyalgia. Elevated hs-CRP confirms systemic inflammation, likely driven by both insulin resistance and adipose tissue cytokine production. Flattened cortisol curve reflects HPA axis exhaustion consistent with the hypocortisolism documented by Riva et al. (2010), removing cortisol’s normal anti-inflammatory brake. Organic acids patterns suggest mitochondrial dysfunction consistent with the findings of Cordero et al. (2010). Previous pregabalin trial worsened the metabolic domain through weight gain. Duloxetine addressed the neurotransmitter component but not the metabolic, mitochondrial, or inflammatory drivers.

Individualized Protocol: Metabolic optimization: anti-inflammatory dietary protocol guided by continuous glucose monitoring, targeting insulin sensitivity. Zone 2 cardiovascular exercise 150 minutes per week (graded introduction given pain and deconditioning). Coenzyme Q10 supplementation targeting the NLRP3 inflammasome pathway (Cordero et al., 2014). Omega-3 fatty acid repletion to omega-3 index >8% for specialized pro-resolving mediator production. Vitamin D repletion to 50–80 ng/mL. MOTS-c (5–10 mg subcutaneously three times weekly, morning dosing) targeting AMPK activation and insulin sensitization (Lee et al., Cell Metabolism, 2015). SS-31 (5–10 mg subcutaneously daily) targeting mitochondrial inner membrane stabilization (Szeto, British Journal of Pharmacology, 2014). DSIP (100–200 µg subcutaneously at bedtime) targeting deep sleep restoration for growth hormone release and HPA axis reset. Ipamorelin/CJC-1295 (200–300 µg/100 µg subcutaneously at bedtime, five nights per week) for growth hormone secretion, temporally separated from MOTS-c by at least 8 hours. Reassessment of metabolic markers, inflammatory markers, and cortisol curve at 12 weeks.

6.2 Patient B: Gut-Immune-Neuroendocrine Dominant Pattern

Presentation: 36-year-old woman with 3-year history of widespread pain and prominent gastrointestinal symptoms including bloating, alternating bowel habits, and food sensitivities. Anxiety rated 7/10. Pain 6/10. Fatigue 7/10. BMI 23 (normal weight). Previous trial of milnacipran (nausea, discontinued after 4 weeks). Currently taking no fibromyalgia medications.

Domain Assessment — Laboratory Findings: Fasting insulin 8 µIU/mL (normal), HbA1c 5.2% (normal). hs-CRP 3.1 mg/L (mildly elevated). IL-6 elevated on cytokine panel. Diurnal cortisol curve showing elevated evening cortisol (HPA axis overactivation pattern). Positive SIBO breath test (hydrogen-dominant). Intestinal permeability panel showing elevated zonulin (marker of tight junction disruption). Microbiome analysis showing reduced Bifidobacterium and Faecalibacterium prausnitzii (butyrate-producing species). Vitamin D 32 ng/mL (suboptimal). B12 borderline at 350 pg/mL.

Domain Interpretation: This patient’s pattern is consistent with the gut-immune-brain cascade. Normal metabolic markers indicate the metabolic domain is not the primary driver. Positive SIBO and elevated zonulin confirm gut barrier dysfunction consistent with the microbiome alterations documented by Minerbi et al. (2019) and the SIBO-fibromyalgia association documented by Erdrich et al. (2020). Elevated IL-6 with mildly elevated hs-CRP reflects gut-driven systemic inflammation activating central sensitization pathways. Elevated evening cortisol reflects HPA axis overactivation (the early phase described by Heim et al., 2000), consistent with the anxiety-dominant presentation. Milnacipran’s gastrointestinal side effects likely worsened the gut domain.

Individualized Protocol: SIBO treatment per established protocols. Gut barrier repair: oral BPC-157 (250–500 µg twice daily) targeting epithelial tight junction restoration and mucosal healing (Gwyer et al., Cell and Tissue Research, 2019). KPV (200–400 µg orally twice daily) targeting NF-κB inhibition at the gut mucosal level. Elimination dietary protocol guided by food sensitivity results. Probiotic repletion targeting depleted butyrate-producing species. Selank (250–500 µg subcutaneously two to three times daily) for anxiety and HPA axis modulation without gastrointestinal side effects or sedation (Zozulia et al., Zhurnal Nevrologii i Psikhiatrii, 2008). B12 repletion. Vitamin D optimization to 50–80 ng/mL. Reassessment of SIBO breath test, intestinal permeability, inflammatory markers, and cortisol curve at 12 weeks.

6.3 Patient C: Inflammatory-Structural-Vascular Pattern

Presentation: 55-year-old man with 8-year history of widespread pain, burning and tingling in hands and feet, cold intolerance, and exercise intolerance. Pain 7/10. Previous trials of pregabalin (moderate pain relief at 300 mg but weight gain and edema, currently continuing) and duloxetine (added, partial additional benefit for mood). Skin biopsy performed by referring neurologist showing reduced intraepidermal nerve fiber density consistent with small fiber neuropathy.

Domain Assessment — Laboratory Findings: Fasting insulin 18 µIU/mL (elevated), HbA1c 6.1% (prediabetic). hs-CRP 5.8 mg/L (elevated). TNF-α and IL-6 elevated on cytokine panel. Omega-3 index 2.8% (critically low). Vitamin D 22 ng/mL (deficient). RBC magnesium low. Heavy metal screen showing elevated mercury at 8 µg/L (reference <5). Organic acids showing elevated 8-hydroxy-2-deoxyguanosine (marker of oxidative DNA damage). Confirmed small fiber neuropathy on prior skin biopsy (Uceyler et al., Brain, 2013 documented this finding in fibromyalgia).

Domain Interpretation: This patient demonstrates the metabolic-vascular-neural cascade described in cellular systems theory. Insulin resistance damages the vasa nervorum (the microvasculature feeding peripheral nerves), producing the small fiber neuropathy confirmed on biopsy. Elevated mercury represents a detoxification domain burden with direct neurotoxic effects. High inflammatory markers reflect both metabolic and toxic-burden-driven inflammation. The cold intolerance and exercise intolerance are consistent with the microvascular pathology documented by Albrecht et al. (2013). Pregabalin provides partial calcium-channel-mediated relief but the weight gain and edema are worsening the metabolic and vascular domains. The bimodal symptom pattern — partial pain relief from pregabalin with continued burning/tingling and exercise intolerance — reflects domain-selective treatment response.

Individualized Protocol: Mercury burden reduction through guided chelation with glutathione support (IV glutathione 600–1200 mg one to two times weekly). Metabolic optimization targeting insulin resistance. NAD+ (IV 250–500 mg one to two times weekly for 4-week loading) for mitochondrial energy substrate. GHK-Cu (1–2 mg subcutaneously daily) for nerve outgrowth stimulation and gene expression modulation toward tissue repair (Pickart and Margolina, BioMed Research International, 2014; Pickart et al., International Journal of Molecular Sciences, 2018). TB-500 (750 µg to 1.5 mg subcutaneously twice weekly) for cell migration to damaged nerve tissue and anti-fibrotic remodeling (Malinda et al., Journal of Investigative Dermatology, 1999). MOTS-c for insulin sensitization. Omega-3 repletion, vitamin D optimization, magnesium repletion. Consider pregabalin taper as metabolic and structural domains improve, monitoring pain response. Reassessment of metabolic markers, heavy metal levels, inflammatory markers, and repeat skin biopsy for intraepidermal nerve fiber density at 6 months.

7. Emerging Peptide Therapeutics: Domain-Targeted Intervention

Peptide therapeutics offer the potential for domain-targeted intervention in fibromyalgia. Unlike small-molecule pharmaceuticals that typically modulate a single receptor or transporter, peptides interact with biological signaling pathways that may address domain-level dysfunction. The following peptides have published evidence connecting their mechanisms to biological domains documented as dysfunctional in fibromyalgia. All evidence for their application in fibromyalgia is extrapolated from mechanism-of-action studies and trials in related conditions; no randomized controlled trials of these peptides in fibromyalgia populations have been published.

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) activates AMPK — a master energy-sensing enzyme — to improve insulin sensitivity, promote glucose uptake, and reduce inflammatory cytokines including IL-6 and TNF-α (Lee et al., Cell Metabolism, 2015). MOTS-c levels increase approximately 12-fold in skeletal muscle during exercise, functioning as an endogenous exercise-signaling molecule. Its relevance to fibromyalgia is the direct connection between AMPK activation and the insulin resistance documented by Pappolla et al. (2021). Administered subcutaneously at 5–10 mg three times weekly in the morning. Not FDA-approved.

SS-31 (elamipretide) selectively targets the inner mitochondrial membrane by binding cardiolipin, stabilizing electron transport chain organization and improving bioenergetic efficiency (Szeto, British Journal of Pharmacology, 2014; Birk et al., Journal of Biological Chemistry, 2013). Clinical trials have been completed in primary mitochondrial myopathy (Karaa et al., Neurology, 2018). SS-31 addresses the mitochondrial dysfunction documented by Cordero et al. (2010, 2014) at the membrane level. Administered subcutaneously at 5–10 mg daily. Not FDA-approved for pain indications.

BPC-157 (body protective compound) is a 15-amino-acid peptide with demonstrated anti-inflammatory, angiogenic, and tissue-repair properties in preclinical models (Gwyer et al., Cell and Tissue Research, 2019). It restores gut barrier integrity through epithelial tight junction repair, restores nitric oxide production in blood vessel walls, and reduces intestinal inflammation. Its primary relevance to fibromyalgia is the gut-immune-brain cascade, targeting the upstream gut barrier dysfunction that feeds systemic inflammation. Administered orally at 250–500 µg twice daily. Not FDA-approved.

KPV (lysine-proline-valine) directly inhibits NF-κB (Niederberger and Geisslinger, FASEB Journal, 2008) without suppressing overall immune function, concentrating preferentially in gastrointestinal mucosa. Targets the inflammatory amplification pathway at the gut level. Administered orally at 200–400 µg twice daily. Not FDA-approved.

Selank modulates GABA through allosteric GABAA receptor mechanisms to reduce anxiety without sedation, dependence, or cognitive impairment. In a clinical study of 62 patients with generalized anxiety disorder, anxiolytic effect was comparable to benzodiazepine medazepam with additional antiasthenic effects (Zozulia et al., Zhurnal Nevrologii i Psikhiatrii, 2008; Kasian et al., Frontiers in Pharmacology, 2017). Addresses the anxiety and HPA axis overactivation component of fibromyalgia without the gastrointestinal or metabolic side effects of SSRIs/SNRIs. Administered subcutaneously at 250–500 µg two to three times daily. Not FDA-approved in the United States.

DSIP (delta sleep-inducing peptide) promotes delta-wave deep sleep architecture rather than forcing sedation. Targets the sleep-hormone-repair cascade by restoring the sleep stage during which growth hormone release, tissue repair, and inflammatory resolution occur (Choy, 2015; Finan et al., 2013). Administered subcutaneously at 100–200 µg at bedtime. Not combined with benzodiazepines. Not FDA-approved.

GHK-Cu and TB-500 target the structural domain. GHK-Cu stimulates collagen, elastin, and glycosaminoglycan production, promotes nerve outgrowth, and modulates approximately 32% of human gene expression toward repair patterns (Pickart and Margolina, 2014; Pickart et al., 2018). TB-500 promotes cell migration to injured tissue with anti-fibrotic remodeling (Malinda et al., 1999). Relevant for fibromyalgia patients with documented small fiber neuropathy (Uceyler et al., 2013). Neither FDA-approved.

Peptide protocols are individualized based on domain assessment findings. The clinical scenarios in Section 6 illustrate how peptide selection is directed by laboratory data rather than applied as a standardized protocol. Because peptides operate across multiple biological pathways, many have therapeutic potential beyond the specific domain applications described here. Additional peptides targeting immune regulation, detoxification, and hormonal restoration may be indicated based on individual assessment.

8. Discussion

The evidence reviewed in this paper supports three propositions. First, fibromyalgia involves measurable, objective dysfunction across multiple biological domains, not merely subjective symptom amplification through a single central mechanism. Insulin resistance, NLRP3 inflammasome activation, altered gut microbiome composition, small fiber neuropathy, combined systemic and neuroinflammation, HPA axis dysregulation, and peripheral microvascular pathology have each been independently documented in fibromyalgia populations through peer-reviewed research using validated laboratory and histological measures.

Second, the limited, partial, bimodal response to single-pathway pharmacotherapy is consistent with a multi-domain disorder. If fibromyalgia were primarily a single-pathway disorder, a correctly targeted single-pathway agent would be expected to produce a normally distributed treatment response. Instead, all three FDA-approved agents produce a bimodal response (substantial relief or minimal benefit) in approximately 1 in 10 patients beyond placebo, with no cross-symptom efficacy and no sustained benefit beyond six months. This pattern is the expected signature of a multi-domain disorder treated with single-domain interventions.

Third, the domains are not independent but interact dynamically, creating self-reinforcing cascades that maintain the syndrome even when individual components are treated. Insulin resistance drives inflammation, which activates central sensitization, which produces pain that worsens insulin resistance. Gut barrier dysfunction feeds systemic inflammation, which feeds central sensitization, which disrupts sleep, which impairs repair. These cascades explain both the chronicity of fibromyalgia and the inadequacy of single-point intervention.

Cellular systems theory does not claim to identify a single root cause of fibromyalgia. It proposes that the condition emerges from the dynamic interaction of multiple biological domains, that the specific combination of domain dysfunction varies between patients, and that effective treatment requires identifying and addressing the dominant domains in each individual through objective laboratory assessment. This framework shifts the clinical question from “which single medication should this patient receive?” to “which biological domains are dysfunctional in this patient, and how can they be addressed simultaneously?”

Limitations of this review include the narrative methodology, the small sample sizes of key studies (particularly Pappolla et al., 2021, with 33 patients), the preclinical nature of most peptide evidence, and the absence of randomized controlled trials testing the multi-domain intervention approach in fibromyalgia. Prospective studies comparing individualized domain-targeted protocols with standardized pharmacotherapy are needed to test the clinical predictions of cellular systems theory.

9. Conclusion

Fibromyalgia is classified and treated as a single-pathway central sensitization disorder, yet the published evidence demonstrates multi-domain biological dysfunction and the clinical data demonstrate limited single-pathway treatment efficacy. Cellular systems theory provides a framework for reconciling these observations: fibromyalgia is a multi-system cellular disorder in which variable domain dysfunction across metabolic, mitochondrial, inflammatory, neuroendocrine, microbiome, vascular, and structural systems produces the clinical syndrome, and the variable treatment response reflects the variable biological terrain across patients. Individualized, domain-specific intervention guided by functional laboratory assessment — including emerging peptide therapeutics targeting the documented domain dysfunction — represents a logical extension of the evidence base and warrants prospective clinical investigation.

Author Information

Ty Thomas, MD, is CEO and Medical Director of Alabama Pain Physicians, a board-certified interventional pain practice in Birmingham and Bessemer, Alabama. Dr. Thomas is board-certified in Physical Medicine and Rehabilitation with additional certification in Venous and Lymphatic Medicine. Alabama Pain Physicians integrates functional laboratory assessment and metabolic optimization with conventional pain management. Contact: 205.332.3160. BamaPain.com.

Disclosures: The author reports no external conflicts of interest relevant to this manuscript. Alabama Pain Physicians offers the laboratory panels and peptide therapeutics described in this review as clinical services. No external funding was received for this work.

References

1. Häuser W, Ablin J, Fitzcharles MA, et al. Fibromyalgia. Nat Rev Dis Primers. 2015;1:15022.

2. Sarzi-Puttini P, Giorgi V, Marotto D, Atzeni F. Fibromyalgia: an update. Nat Rev Rheumatol. 2020;16(11):645-660.

3. Soroosh S, et al. Epidemiology of fibromyalgia: East versus West. Int J Rheum Dis. 2024;27(12):e15428.

4. Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311(15):1547-1555.

5. Buskila D. Epidemiology of fibromyalgia. Curr Pain Headache Rep. 2003;7(5):362-368.

6. Woolf CJ. Central sensitization: implications for diagnosis and treatment of pain. Pain. 2011;152(3 Suppl):S2-S15.

7. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity. J Pain. 2009;10(9):895-926.

8. Moore RA, Derry S, Aldington D, et al. Effectiveness of pharmacological therapies for fibromyalgia: overview of Cochrane Reviews. Rheumatology. 2025;64(5):keae707.

9. Derry S, Cording M, Wiffen PJ, et al. Pregabalin for pain in fibromyalgia in adults. Cochrane Database Syst Rev. 2016;9:CD011790.

10. Straube S, Derry S, Moore RA, et al. Pregabalin in fibromyalgia: responder analysis from individual patient data. BMC Musculoskelet Disord. 2010;11:150.

11. Lunn MPT, Hughes RAC, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014;1:CD007115.

12. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia: systematic review of randomised trials. BMC Neurol. 2008;8:29.

13. Moore RA, Cai N, Skljarevski V, Tolle TR. Duloxetine use in chronic painful conditions: individual patient data responder analysis. Eur J Pain. 2014;18(1):67-75.

14. Pappolla MA, et al. Insulin resistance is associated with central pain in fibromyalgia. Pain Physician. 2021;24(2):175-184.

15. Cordero MD, et al. NLRP3 inflammasome is activated in fibromyalgia: effect of CoQ10. J Clin Med. 2014;3(4):1242-1263.

16. Cordero MD, et al. Oxidative stress and mitochondrial dysfunction in fibromyalgia. Neuro Endocrinol Lett. 2010;31(2):169-173.

17. Meeus M, et al. Mitochondrial dysfunctions in chronic pain/fatigue syndromes. Med Hypotheses. 2013;80(4):389-397.

18. Bäckryd E, et al. Systemic inflammation and neuroinflammation in fibromyalgia. J Pain Res. 2017;10:515-525.

19. Uçeyler N, Häuser W, Sommer C. Cytokines in fibromyalgia syndrome. BMC Musculoskelet Disord. 2011;12:245.

20. Littlejohn G, Guymer E. Neurogenic inflammation in fibromyalgia. Semin Immunopathol. 2018;40(3):291-300.

21. Theoharides TC, et al. Mast cells, neuroinflammation and pain in fibromyalgia. Front Cell Neurosci. 2019;13:353.

22. Niederberger E, Geisslinger G. The IKK-NF-κB pathway. FASEB J. 2008;22(10):3432-3442.

23. Riva R, et al. Fibromyalgia is associated with hypocortisolism. Int J Behav Med. 2010;17(3):223-233.

24. Heim C, Ehlert U, Hellhammer DH. Hypocortisolism in stress-related disorders. Psychoneuroendocrinology. 2000;25(1):1-35.

25. McBeth J, et al. HPA axis function in chronic widespread pain. J Rheumatol. 2005;32(7):1322-1328.

26. Choy EH. The role of sleep in pain and fibromyalgia. Nat Rev Rheumatol. 2015;11(9):513-520.

27. Finan PH, Goodin BR, Smith MT. Sleep and pain association. J Pain. 2013;14(12):1539-1552.

28. Watkins LR, Maier SF. Immune and glial cells in pathological pain. Physiol Rev. 2002;82(4):981-1011.

29. Minerbi A, et al. Altered microbiome in fibromyalgia. Pain. 2019;160(11):2589-2602.

30. Erdrich S, et al. Fibromyalgia and SIBO. Clin Exp Rheumatol. 2020;38(Suppl 123):165-175.

31. Camilleri M. Leaky gut: mechanisms and implications. Gut. 2019;68(8):1516-1526.

32. Ozgocmen S, et al. Antioxidant status in fibromyalgia. Clin Rheumatol. 2006;25(4):462-467.

33. Albrecht PJ, et al. Excessive sensory innervation of cutaneous AVS in fibromyalgia. Pain Med. 2013;14(6):895-915.

34. Uceyler N, et al. Small fibre pathology in fibromyalgia. Brain. 2013;136(Pt 6):1857-1867.

35. Zhai X, et al. Chronic pain and insulin resistance. J Pain. 2016;17:404-413.

36. Lee C, et al. MOTS-c promotes metabolic homeostasis. Cell Metab. 2015;21(3):443-454.

37. Szeto HH. Cardiolipin-protective compound for mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029-2050.

38. Birk AV, et al. SS-31 re-energizes mitochondria via cardiolipin. JASN. 2013;24(8):1250-1261.

39. Karaa A, et al. Elamipretide trial in mitochondrial myopathy. Neurology. 2018;90(14):e1212-e1221.

40. Gwyer D, et al. BPC 157 in musculoskeletal healing. Cell Tissue Res. 2019;377(2):153-159.

41. Zozulia AA, et al. Selank in generalized anxiety and neurasthenia. Zh Nevrol Psikhiatr. 2008;108(4):38-48.

42. Kasian A, et al. Selank and GABAergic neurotransmission. Front Pharmacol. 2017;8:89.

43. Pickart L, Margolina A. GHK and DNA: resetting the genome. BioMed Res Int. 2014;2014:151479.

44. Pickart L, et al. GHK-Cu regenerative actions. Int J Mol Sci. 2018;19(7):1987.

45. Malinda KM, et al. Thymosin beta4 in wound healing. J Invest Dermatol. 1999;113(3):364-368.

46. Helde-Frankling M, Björkhem-Bergman L. Vitamin D in pain management. Int J Mol Sci. 2017;18(10):2170.

© 2026 Alabama Pain Physicians. All rights reserved.